Medical Director, Clinical ScienceBioMarin Pharmaceutical Inc., Novato, CA, USANovato, California, United States
OC 20.1 - Bleeding, FVIII activity, and safety 3 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1
Sunday, June 25, 202314:45 – 15:00 ET
PB0626 - Quantitative pharmacokinetic model to characterize and extrapolate long-term FVIII activity levels in patients with severe hemophilia A treated with valactocogene roxaparvovec
Monday, June 26, 202318:30 – 19:30 ET
